Karakurt F, Kargili A, Kasapoglu B
Endocrinology Department, Fatih University Hospital, 06510 Ankara Turkey.
Exp Clin Endocrinol Diabetes. 2010 Feb;118(2):96-7. doi: 10.1055/s-0029-1234065. Epub 2009 Oct 15.
Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.
吡格列酮用于改善2型糖尿病患者的胰岛素敏感性。这类药物通常耐受性良好；然而，其使用可能与多种不良反应相关，包括水肿、体重增加、黄斑水肿和心力衰竭。在此，我们报告1例在口服吡格列酮治疗糖尿病第7天出现全血细胞减少的患者，停药6天后完全康复。据我们所知，这是首例报道的由吡格列酮治疗引起的全血细胞减少病例。
